to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.
Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera.
Intralaboratory reliability of serologic and urine testing for Lyme disease.
Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms.
Inhibition of neutrophil Fc receptor function by cotricosteroids.
Disorders of phagocyte chemotaxis.
Immunoglobulin A, Secretory
Immunoglobulin Fc Fragments
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
Association of immune response to endothelial cell growth factor with early disseminated and late manifestations of Lyme disease but not posttreatment Lyme disease syndrome.
Preformulation Characterization and Stability Assessments of Secretory IgA Monoclonal Antibodies as Potential Candidates for Passive Immunization by Oral Administration.
Oral administration of an anti-CfaE secretory IgA antibody protects against Enterotoxigenic Escherichia coli diarrheal disease in a nonhuman primate model.
A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction.
IgA as a potential candidate for enteric monoclonal antibody therapeutics with improved gastrointestinal stability.
Highly Specific Mouse Anti-Joining Chain of Human Immunoglobulin A.
Investigation of a monoclonal antibody against enterotoxigenic Escherichia coli, expressed as secretory IgA1 and IgA2 in plants.
Enteric Polymer-Coated Porous Silicon Nanoparticles for Site-Specific Oral Delivery of IgA Antibody.
Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants.
Immunoglobulin Variable Region